MCID: ACT011
MIFTS: 35

Acute Contagious Conjunctivitis

Categories: Eye diseases

Aliases & Classifications for Acute Contagious Conjunctivitis

MalaCards integrated aliases for Acute Contagious Conjunctivitis:

Name: Acute Contagious Conjunctivitis 12 15 72
Pink Eye 12 3
Pinkeye 12 43
Keratoconjunctivitis Due to Mycoplasma Conjunctivae 72
Contagious Opthalmia 12
Conjunctivitis 72

Classifications:



External Ids:

Disease Ontology 12 DOID:11213
NCIt 50 C35704
SNOMED-CT 68 17482009
UMLS 72 C0009763 C1261274 C1313983

Summaries for Acute Contagious Conjunctivitis

MedlinePlus : 43 Conjunctivitis is the medical name for pink eye. It involves inflammation of the outer layer of the eye and inside of the eyelid. It can cause swelling, itching, burning, discharge, and redness. Causes include Bacterial or viral infection Allergies Substances that cause irritation Contact lens products, eye drops, or eye ointments Pinkeye usually does not affect vision. Infectious pink eye can easily spread from one person to another. The infection will clear in most cases without medical care, but bacterial pinkeye needs treatment with antibiotic eye drops or ointment. NIH: National Eye Institute

MalaCards based summary : Acute Contagious Conjunctivitis, also known as pink eye, is related to conjunctivitis and eye disease, and has symptoms including fever, pruritus and bloodshot eye. An important gene associated with Acute Contagious Conjunctivitis is OCA2 (OCA2 Melanosomal Transmembrane Protein). The drugs Pheniramine and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotype is Increased virus production.

Disease Ontology : 12 A bacterial acute conjunctivitis that is characterized by highly contagious conjunctival hypermia and mucopurulent discharge and has material basis in Hemophilius Aegypticus.

CDC : 3 People often call conjunctivitis "pink eye" because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

Related Diseases for Acute Contagious Conjunctivitis

Diseases related to Acute Contagious Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 21)
# Related Disease Score Top Affiliating Genes
1 conjunctivitis 11.7
2 eye disease 11.6
3 albinism, oculocutaneous, type ii 11.4
4 muckle-wells syndrome 11.2
5 zika fever 11.2
6 albinism, oculocutaneous, type iii 11.1
7 agammaglobulinemia, x-linked 11.1
8 ocular albinism 11.1
9 inclusion conjunctivitis 11.1
10 blepharoconjunctivitis 11.1
11 measles 11.1
12 albinism 11.1
13 hypomelanotic disorder 11.1
14 keratoconjunctivitis 10.4
15 keratitis, hereditary 10.3
16 chlamydia 10.1
17 anisocoria 9.9
18 acute hemorrhagic conjunctivitis 9.9
19 trachoma 9.9
20 fibrosarcoma 9.9
21 acute conjunctivitis 9.5 PIGQ OCA2

Graphical network of the top 20 diseases related to Acute Contagious Conjunctivitis:



Diseases related to Acute Contagious Conjunctivitis

Symptoms & Phenotypes for Acute Contagious Conjunctivitis

UMLS symptoms related to Acute Contagious Conjunctivitis:


fever, pruritus, bloodshot eye, conjunctival congestion, redness of eye, discharge from eye

GenomeRNAi Phenotypes related to Acute Contagious Conjunctivitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased virus production GR00378-A 8.62 CCL7 PIGQ

Drugs & Therapeutics for Acute Contagious Conjunctivitis

Drugs for Acute Contagious Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 276)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pheniramine Approved Phase 4 86-21-5 4761
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
4
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
5
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
6
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
7
Povidone Approved Phase 4 9003-39-8
8
Iodine Approved, Investigational Phase 4 7553-56-2 807
9
Povidone-iodine Approved Phase 4 25655-41-8
10
Alcaftadine Approved Phase 4 147084-10-4 19371515
11
Bepotastine Approved Phase 4 125602-71-3, 190786-44-8 2350
12
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
13
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
14
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
16
Ofloxacin Approved Phase 4 82419-36-1 4583
17
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
18
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
19
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
20
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
21
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
22
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
23
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
24
Dipivefrin Approved Phase 4 52365-63-6 3105
25
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
26
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
27
Montelukast Approved Phase 4 158966-92-8 5281040
28
Ranibizumab Approved Phase 4 347396-82-1 459903
29
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
30
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
31
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
32
Tranilast Investigational Phase 4 53902-12-8 93543
33
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
34 Ketorolac Tromethamine Phase 4
35 Keratolytic Agents Phase 4
36 Ophthalmic Solutions Phase 4
37 Anti-Infective Agents Phase 4
38 Anti-Bacterial Agents Phase 4
39 Topoisomerase Inhibitors Phase 4
40 Polymyxins Phase 4
41 cadexomer iodine Phase 4
42 Dermatologic Agents Phase 4
43 Antipruritics Phase 4
44 Immunosuppressive Agents Phase 4
45 Calcineurin Inhibitors Phase 4
46 Hormone Antagonists Phase 4
47 Antiemetics Phase 4
48 Gastrointestinal Agents Phase 4
49 HIV Protease Inhibitors Phase 4
50 glucocorticoids Phase 4

Interventional clinical trials:

(show top 50) (show all 451)
# Name Status NCT ID Phase Drugs
1 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
2 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
3 A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Unknown status NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
4 To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™) Unknown status NCT01808768 Phase 4 Alcaftadine
5 The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
6 Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma Unknown status NCT02277483 Phase 4 LAIS®
7 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
8 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
9 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
10 Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
11 A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis. Completed NCT00581542 Phase 4 moxifloxacin;polytrim
12 A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
13 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
14 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
15 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
16 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
17 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
18 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
19 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2% Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
20 Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
21 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
22 A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
23 A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model Completed NCT00534794 Phase 4 Elestat;Pataday
24 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
25 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
26 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
27 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
28 A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
29 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
30 Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
31 A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms Completed NCT00311844 Phase 4 desloratadine
32 A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
33 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
34 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
35 A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
36 A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
37 Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings Completed NCT01433510 Phase 4 Grazax
38 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4 loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
39 A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC) Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
40 A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
41 Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
42 Single Center, Randomized, Double-Masked Evaluation of the Efficacy of Prednisolone Acetate 1% Ophthalmic Suspension Compared to Prednisolone Acetate 0.12% Ophthalmic Suspension, Loteprednol Etabonate 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
43 A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
44 Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® Completed NCT02437786 Phase 4 GRAZAX
45 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
46 A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Birch Given With a Rush Up-dosing Regimen to Patients With Allergic Rhinitis/Rhinoconjunctivitis Completed NCT01918956 Phase 4
47 A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis Completed NCT02256553 Phase 4 Rescue Medication
48 A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis Completed NCT01059266 Phase 4 PURETHAL Grasses, 20.000 AUM/ml
49 Bilastine and Montelukast in Patients With Seasonal Allergic Rhinoconjunctivitis and Asthma: Efficacy of Concomitant Administration - the SKY Study Completed NCT02761252 Phase 4 Bilastine 20mg;Montelukast 10mg;Placebo Bilastine 20mg;Placebo Montelukast 10mg
50 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication

Search NIH Clinical Center for Acute Contagious Conjunctivitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cromolyn
Cromolyn Sodium
Oxymetazoline
Oxymetazoline hydrochloride
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate

Genetic Tests for Acute Contagious Conjunctivitis

Anatomical Context for Acute Contagious Conjunctivitis

MalaCards organs/tissues related to Acute Contagious Conjunctivitis:

41
Eye, Testes, Skin, Bone, Salivary Gland, Thyroid, Retina

Publications for Acute Contagious Conjunctivitis

Articles related to Acute Contagious Conjunctivitis:

(show top 50) (show all 52)
# Title Authors PMID Year
1
Efficacy of Houttuynia eye drops for the treatment of vernal keratoconjunctivitis: A systemic review and meta-analysis protocol. 17
31261561 2019
2
Prevention of Gonococcal Eye Infection in Newborns. 17
30694323 2019
3
Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum: US Preventive Services Task Force Reaffirmation Recommendation Statement. 17
30694327 2019
4
A multiplex real-time PCR assay for the detection and differentiation of five bovine pinkeye pathogens. 38
30930057 2019
5
Inhibitory effect of chitooligosaccharides on retinol metabolism and bioavailability in mice. 38
31353518 2019
6
Large genomic differences between Moraxella bovoculi isolates acquired from the eyes of cattle with infectious bovine keratoconjunctivitis versus the deep nasopharynx of asymptomatic cattle. 38
26872821 2016
7
Infectious bovine keratoconjunctivitis (pinkeye). 38
25576389 2015
8
Moraxella spp. isolated from field outbreaks of infectious bovine keratoconjunctivitis: a retrospective study of case submissions from 2010 to 2013. 38
25261461 2014
9
Genome-wide association study of infectious bovine keratoconjunctivitis in Angus cattle. 38
23530766 2013
10
Genetic parameters of infectious bovine keratoconjunctivitis and its relationship with weight and parasite infestations in Australian tropical Bos taurus cattle. 38
22839739 2012
11
Descriptive epidemiology of Moraxella bovis, Moraxella bovoculi and Moraxella ovis in beef calves with naturally occurring infectious bovine keratoconjunctivitis (Pinkeye). 38
21962410 2012
12
A randomized clinical trial evaluating a farm-of-origin autogenous Moraxella bovis vaccine to control infectious bovine keratoconjunctivis (pinkeye) in beef cattle. 38
22092641 2011
13
Whole genome analysis of infectious bovine keratoconjunctivitis in Angus cattle using Bayesian threshold models. 38
21645302 2011
14
Association of toll-like receptor four single nucleotide polymorphisms with incidence of infectious bovine keratoconjunctivitis (IBK) in cattle. 38
20938658 2011
15
Impact of online primary care visits on standard costs: a pilot study. 38
20415617 2010
16
Recombinant Moraxella bovoculi cytotoxin-ISCOM matrix adjuvanted vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis. 38
20217228 2010
17
Moraxella bovoculi and infectious bovine keratoconjunctivitis: cause or coincidence? 38
20117543 2010
18
Assessing genotypic variability of cowpea (Vigna unguiculata [L.] Walp.) to current and projected ultraviolet-B radiation. 38
18723366 2008
19
A putative quantitative trait locus on chromosome 20 associated with bovine pathogenic disease incidence. 38
18502878 2008
20
Ribosomal RNA-based analysis of the bacterial flora from the conjunctivae of cattle with bovine keratoconjunctivitis (BKC). 38
18513895 2008
21
Ocular plague (Yersinia pestis) in mule deer (Odocoileus hemionus) from Wyoming and Oregon. 38
18957655 2008
22
Assessment of methodological quality and sources of variation in the magnitude of vaccine efficacy: a systematic review of studies from 1960 to 2005 reporting immunization with Moraxella bovis vaccines in young cattle. 38
18054816 2008
23
Prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant Moraxella bovis pilin-Moraxella bovis cytotoxin-ISCOM matrix adjuvanted vaccine. 38
17656049 2007
24
Expression, purification and characterization of recombinant phospholipase B from Moraxella bovis with anomalous electrophoretic behavior. 38
17709258 2007
25
Moraxella bovoculi sp. nov., isolated from calves with infectious bovine keratoconjunctivitis. 38
17392208 2007
26
Putative quantitative trait loci associated with the probability of contracting infectious bovine keratoconjunctivitis. 38
17093209 2006
27
Identification of a capsular polysaccharide from Moraxella bovis. 38
15721351 2005
28
Diagnosis of a mixed mycoplasma infection associated with a severe outbreak of bovine pinkeye in young calves. 38
15586576 2004
29
Efficacy of different dosage levels and administration routes of tilmicosin in a natural outbreak of infectious bovine keratoconjunctivitis (pinkeye). 38
19750751 2002
30
Resistance to Cucumber mosaic virus in Cowpea and Implications for Control of Cowpea Stunt Disease. 38
30823082 2001
31
First Report of Cowpea Aphid-Borne Mosaic Potyvirus from Cowpeas Grown Commercially in the U.S. 38
30866397 1997
32
Annual disease incidence in Colorado cow-calf herds participating in rounds 2 and 3 of the National Animal Health Monitoring System from 1986 to 1988. 38
2032921 1991
33
Exclusion of infectious diseases from sheep and goat farms. 38
2245370 1990
34
An outbreak of keratoconjunctivitis (pinkeye) in sheep. 38
17423245 1989
35
Development of ocular inserts for cattle. 38
3616580 1987
36
Linkage of loci encoding a kidney endothelial antigen and fumarate hydratase (Fh-1) in the rat. 38
3910024 1985
37
Relationship of the face fly (Diptera: Muscidae) to pinkeye in cattle: a review and synthesis of the relevant literature. 38
6387122 1984
38
Pigment mutations associated with altered circadian rhythms in mice. 38
7079353 1982
39
Differentiating pinkeye from sore-eye. 38
7061330 1982
40
Pursuing a practical solution to bovine pinkeye. 38
6915684 1981
41
Field association of female face flies with Moraxella bovis, an etiological agent of bovine pinkeye. 38
7198659 1981
42
A "pinkeye-like" condition in deer. 38
6936673 1980
43
Experimental infectious bovine keratoconjunctivitis: effects of feeding colostrum from vaccinated cows on development of pinkeye in calves. 38
7224284 1980
44
A survey of bovine infectious keratitis (pinkeye) in beef cattle. 38
6930060 1980
45
Pinkeye (bovine infectious keratoconjunctivitis) in beef cattle. 38
574506 1979
46
Complementation and noncomplementation in heterokaryons of three unlinked pigment mutants of the fowl. 38
494058 1979
47
Treatment for pinkeye in cattle. 38
958194 1976
48
Surgical treatment of advanced pinkeye in cattle. 38
4496871 1974
49
Impact of pinkeye (infectious bovine kerato-conjunctivitis) on weaning and postweaning performance of Hereford calves. 38
4836826 1974
50
Evaluation of tylocin-neomycin powder in treatment of bovine pinkeye. 38
4492811 1974

Variations for Acute Contagious Conjunctivitis

Expression for Acute Contagious Conjunctivitis

Search GEO for disease gene expression data for Acute Contagious Conjunctivitis.

Pathways for Acute Contagious Conjunctivitis

GO Terms for Acute Contagious Conjunctivitis

Sources for Acute Contagious Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....